Effects of the glutamate carboxypeptidase II (GCP2 1561C>T) and reduced folate carrier (RFC1 80G>A) allelic variants on folate and total homocysteine levels in kidney transplant patients

被引:44
作者
Winkelmayer, WC
Eberle, C
Sunder-Plassmann, G
Födinger, M
机构
[1] Univ Vienna, Div Nephrol & Dialysis, Dept Med 3, A-1090 Vienna, Austria
[2] Harvard Univ, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Sch Med, Boston, MA 02115 USA
[3] Univ Vienna, Inst Med & Chem Lab Diagnost, Vienna, Austria
关键词
GCP; RFC1; genetic polymorphism; mutation; folate; homocysteine; kidney transplants;
D O I
10.1046/j.1523-1755.2003.00025.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. The effect of the glutamate carboxypeptidase II GCP2 1561C>T and the reduced folate carrier 1 RFC1 80G>A polymorphisms on folate and total homocysteine (tHcy) plasma levels of kidney transplant patients are unknown. Methods. In a cross-sectional study of 730 kidney allograft recipients, GCP2 1561C>T, RFC1 80G>A, folate, and tHcy plasma levels were analyzed using linear regression models that allowed dependent covariates to follow a gamma distribution for univariate and multivariate analyses. Results. The allele frequency for GCP2 1561C>T was 0.05, and 0.43 for RFC1 80G>A. Heterozygosity or homozygosity for GCP2 1561C>T was associated with higher folate plasma levels compared to patients without mutation (P<0.0001), while RFC1 80G>A showed no influence. Multiple testing, also including MTHFR 677C>T and MTHFR 1298A>C, revealed no interaction between the different genotypes and the folate plasma concentration. Neither GCP2 1561C>T nor RFC1 80G>A showed an association with tHcy plasma levels. Conclusion. We conclude that GCP2 1561C>T is associated with elevated folate levels. GCP2 1561C>T and RFC1 80G>A are no major determinants of tHcy plasma levels in kidney transplant patients.
引用
收藏
页码:2280 / 2285
页数:6
相关论文
共 24 条
  • [1] ANTONY AC, 1992, BLOOD, V79, P2807
  • [2] Bostom AG, 1999, J AM SOC NEPHROL, V10, P891
  • [3] A polymorphism (80G-&gt;A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia
    Chango, A
    Emery-Fillon, N
    de Courcy, GP
    Lambert, D
    Pfister, M
    Rosenblatt, DS
    Nicolas, JP
    [J]. MOLECULAR GENETICS AND METABOLISM, 2000, 70 (04) : 310 - 315
  • [4] Chiao JH, 1997, J BIOL CHEM, V272, P11165, DOI 10.1074/jbc.272.17.11165
  • [5] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE
    COCKCROFT, DW
    GAULT, MH
    [J]. NEPHRON, 1976, 16 (01) : 31 - 41
  • [6] Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia
    Devlin, AM
    Ling, EH
    Peerson, JM
    Fernando, S
    Clarke, R
    Smith, AD
    Halsted, CH
    [J]. HUMAN MOLECULAR GENETICS, 2000, 9 (19) : 2837 - 2844
  • [7] Methods for analyzing health care utilization and costs
    Diehr, P
    Yanez, D
    Ash, A
    Hornbrook, M
    Lin, DY
    [J]. ANNUAL REVIEW OF PUBLIC HEALTH, 1999, 20 : 125 - 144
  • [8] K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification - Foreword
    Eknoyan, G
    Levin, NW
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (02) : S14 - S266
  • [9] Födinger M, 2000, J NEPHROL, V13, P20
  • [10] Födinger M, 2000, J AM SOC NEPHROL, V11, P1918, DOI 10.1681/ASN.V11101918